Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Neutral rating

Analyst Ratings For Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)

Story continues below

Today, Goldman Sachs Group initiated coverage on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) with a Neutral.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) is Buy with a consensus target price of $37.50 per share, a potential 53.12% upside.

Some recent analyst ratings include

  • 7/26/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
  • 7/17/2018-Wells Fargo & Co initiated coverage with a Outperform rating.
  • 7/17/2018-William Blair initiated coverage with a Outperform rating.
  • 7/17/2018-Jefferies Financial Group initiated coverage with a Buy rating.


    Recent Trading Activity for Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Shares of Autolus Therapeutics Ltd – ADR closed the previous trading session at 24,49 +0,14 0,57 % with 25.56 shares trading hands.

    An ad to help with our costs